NCT01527773|Completed
Phenotypes and Vascular Damage in Chronic Obstructive Pulmonary Disease (COPD)
TOPDOCS
The Obstructive Pulmonary Disease Outcomes Cohort of Switzerland (TOP DOCS): Phenotypes and Vascular Damage in COPD
Loading search results
TOPDOCS
The Obstructive Pulmonary Disease Outcomes Cohort of Switzerland (TOP DOCS): Phenotypes and Vascular Damage in COPD
Sponsor study identifier
observational
313
1 country
1
Study Start
May 2011
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
January 2017
Actual (reported)Study Completion
January 2017
Actual (reported)TOPDOCS is a prospective cohort study including COPD patients from currently six study centers in Switzerland. Patients with COPD GOLD stages I-IV will be enrolled and followed-up annually for at least 3 years. Yearly assessments will include a detailed patient history, quality of life and activity questionnaires, history of exacerbations, lung function, measurements of exercise capacity, measurements of vascular function, exhaled breath analysis and blood sampling. The overall objective of the project is to establish a meticulously characterized cohort of COPD patients living in Switzerland in order to allow high quality research on the pathogenesis, treatment and complications of COPD. The specific aim of the project is to determine clinically relevant COPD phenotypes and biological factors influencing vascular function in COPD patients.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 2017
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 2011
Date type not reportedThis date has not been verified as actual or estimated.
January 18, 2012
Actual (reported)February 7, 2012
Actual (reported)January 2017
Actual (reported)January 2017
Actual (reported)Lung function
FEV1
The change from baseline in lung function at 3 years
Exacerbations
The number of exacerbations observed within 3 years
Cardiovascular risk score
The change from baseline in risk score function at 3 years
BODE-index
The change from baseline in BODE-index at 3 years
Quality of life
The change from baseline in quality of life scale at 3 years
Blood pressure
The change from baseline in mean blood pressure at 3 years
Cohort of patients with proven COPD
Patients with proven COPD, GOLD stages I-IV
University Hospital Zurich, Pneumology
Zurich, Canton of Zurich, 8091, Switzerland
Roeder M, Sievi NA, Kohlbrenner D, Clarenbach CF, Kohler M. Arterial Stiffness Increases Over Time in Relation to Lung Diffusion Capacity: A Longitudinal Observation Study in COPD. Int J Chron Obstruct Pulmon Dis. 2020 Jan 23;15:177-187. doi: 10.2147/COPD.S234882. eCollection 2020.
Sievi NA, Brack T, Brutsche MH, Frey M, Irani S, Leuppi JD, Thurnheer R, Kohler M, Clarenbach CF. "Can do, don't do" are not the lazy ones: a longitudinal study on physical functioning in patients with COPD. Respir Res. 2020 Jan 20;21(1):27. doi: 10.1186/s12931-020-1290-9.
Blood samples
Malcolm Kohler, MD
University Hospital Zurich, Division of Pneumology
313 participants (actual enrollment reported by the registry).
First Submitted
January 18, 2012
First Posted
February 7, 2012
Study Start
May 2011
Date type not reportedThis date has not been verified as actual or estimated.
Nocturnal Breathing and Sleep in Patients With Chronic Obstructive Pulmonary Disease Staying at Altitude
Validation of the 1-minute Sit-to-stand Test in Patients With COPD
Contact the study team to confirm eligibility.
Sievi NA, Kohler M, Thurnheer R, Leuppi JD, Irani S, Frey M, Brutsche M, Brack T, Clarenbach CF. No impact of exacerbation frequency and severity on the physical activity decline in COPD: a long-term observation. Int J Chron Obstruct Pulmon Dis. 2019 Feb 15;14:431-437. doi: 10.2147/COPD.S188710. eCollection 2019.
Sievi NA, Brack T, Brutsche MH, Frey M, Irani S, Leuppi JD, Thurnheer R, Kohler M, Clarenbach CF. Physical activity declines in COPD while exercise capacity remains stable: A longitudinal study over 5 years. Respir Med. 2018 Aug;141:1-6. doi: 10.1016/j.rmed.2018.06.013. Epub 2018 Jun 18.
Clarenbach CF, Sievi NA, Kohler M. Annual progression of endothelial dysfunction in patients with COPD. Respir Med. 2017 Nov;132:15-20. doi: 10.1016/j.rmed.2017.09.005. Epub 2017 Sep 18.
Sievi NA, Franzen D, Kohler M, Clarenbach CF. Physical inactivity and arterial stiffness in COPD. Int J Chron Obstruct Pulmon Dis. 2015 Sep 10;10:1891-7. doi: 10.2147/COPD.S90943. eCollection 2015.
Sievi NA, Senn O, Brack T, Brutsche MH, Frey M, Irani S, Leuppi JD, Thurnheer R, Franzen D, Kohler M, Clarenbach CF. Impact of comorbidities on physical activity in COPD. Respirology. 2015 Apr;20(3):413-8. doi: 10.1111/resp.12456. Epub 2015 Jan 6.
Schonmann M, Sievi NA, Clarenbach CF, Brack T, Brutsche M, Frey M, Irani S, Leuppi JD, Ruediger J, Senn O, Thurnheer R, Kohler M. Physical activity and the frequency of acute exacerbations in patients with chronic obstructive pulmonary disease. Lung. 2015 Feb;193(1):63-70. doi: 10.1007/s00408-014-9673-7. Epub 2014 Dec 13.
Primary Completion
January 2017
Actual (reported)Study Completion
January 2017
Actual (reported)Last Updated
August 11, 2017
Record last verified: 2017-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: